Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Sunday, Arrowhead Pharmaceuticals Announces New Phase 2 Data Of Plozasiran Published In JAMA Cardiology And Presented At ACC.24

Author: Benzinga Newsdesk | April 08, 2024 02:54am

- Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
- SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated

Posted In: ARWR